3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Interventions
pembrolizumab
66
Cyclophosphamide
44
Cisplatin
43
Nivolumab
36
Paclitaxel
32
Carboplatin
31
Radiotherapy
29
Gemcitabine
28
Docetaxel
25
Dexamethasone
22
atezolizumab
21
Doxorubicin
19
Bevacizumab
19
Magnetic Resonance Spectroscopy
17
fludarabine
16
Vincristine
16
Lenalidomide
16
Etoposide
16
Radiosurgery
15
Letrozole
15
Ipilimumab
15
Fluorouracil
15
Blood Specimen Collection
15
palbociclib
14
Rituximab
14
Radiation
14
Leucovorin
14
Cytarabine
14
Surveys and Questionnaires
13
Specimen Handling
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
soluble LAG-3 protein, human
×
90 days
×
Clear all
NCT03625323
2026-04-22
TACTI-002
Immutep S.A.S.
Phase 2
Completed
187 enrolled
13 charts